# Sermorelin Mechanism of Action: GHRH-R → cAMP/PKA → GH → IGF-1 > Sermorelin mechanism of action, explained from the research: GHRH(1-29) binds the pituitary GHRH receptor, raises cAMP/PKA, and drives the body's own pulsatile growth hormone and downstream IGF-1. From receptor to IGF-1: how GHRH(1-29) signals the pituitary to make its own growth hormone — and why the body's brakes stay on. ## Start here The sermorelin mechanism of action is, in one line, *signal the gland, don't replace the hormone*. Sermorelin lands on a receptor on the pituitary's growth-hormone cells and tells them to fire. That order travels through a small relay of molecules inside the cell, and the cell responds by releasing growth hormone in a natural burst. Because the message uses the body's own wiring, the off-switches that normally limit growth hormone still work — so the rhythm stays natural rather than flooded. The rest of this page walks that relay step by step, glossing each term as it appears. ## The receptor: GHRH-R on the somatotroph Sermorelin is GHRH(1-29) — the first 29 amino acids of growth hormone-releasing hormone, and the shortest fragment that retains full activity at its target [4]. That target is the GHRH receptor (GHRH-R), a class-B G-protein-coupled receptor (a common type of cell-surface switch) sitting on somatotrophs — the growth-hormone-producing cells of the anterior pituitary. Receptor engagement is not theoretical. In healthy men, intravenous GHRH(1-29)NH2 elicited measurable GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg — a clean dose-response that anchors the receptor-level pharmacology [3]. Binding does two things at once: it triggers GH release now, and, repeated, it exerts a trophic (growth-promoting) effect on the somatotrophs themselves. ## The relay: cAMP, PKA, and pulsatile GH Inside the cell, the activated receptor couples to Gs, switching on adenylate cyclase — the enzyme that manufactures cyclic AMP (cAMP), the cell's universal 'go' messenger. Rising cAMP activates protein kinase A (PKA), which in turn raises GH gene transcription and prompts secretion. The output is not a steady drip but a pulse: growth hormone leaves the gland in a discrete burst. That pulsatility matters, and it is the whole reason an upstream secretagogue is interesting. Because sermorelin works through the native pathway, the opposing hormone somatostatin (the 'stop' signal) and downstream IGF-1 feedback stay intact, preserving the body's natural pulsatile pattern of GH release rather than overriding it [4]. A single subcutaneous dose keeps serum GH elevated for roughly three hours before the system resets [3]. ## The output: hepatic IGF-1 Growth hormone's effects are largely carried out by IGF-1 (insulin-like growth factor 1), made mainly in the liver in response to GH. So the mechanism's measurable endpoint, downstream, is a rise in IGF-1. The data bear this out across populations. In older men, 0.5-1 mg subcutaneous twice daily for 14 days produced dose-related IGF-1 increases, and at the high dose their IGF-1 levels became indistinguishable from those of young men [2]. In a controlled trial of older adults, a daily GHRH analog raised IGF-1 by 117% — and, importantly, kept it within the physiologic range rather than overshooting it [6]. Read step by step, the cascade is: GHRH-R → cAMP/PKA → pulsatile GH → hepatic IGF-1, with somatostatin and IGF-1 feedback intact throughout. ## Sermorelin vs Ipamorelin Sermorelin and ipamorelin both raise growth hormone, but they pull different levers. Sermorelin is a GHRH analog acting on the GHRH receptor. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts on a *separate* receptor — the ghrelin/GHS receptor. Different doors into the same room. Because they engage distinct receptors, research-user discussions often frame them as complementary rather than interchangeable: one mimics the hypothalamic GHRH signal, the other mimics the ghrelin signal. This page describes the receptor pharmacology; it is not a protocol. The two 2025 reviews that survey the GHRH-analog landscape keep this GHRH-versus-ghrelin distinction front and center [13][14]. ## Sermorelin vs CJC-1295 Both sermorelin and CJC-1295 are GHRH analogs — same receptor, same upstream logic. The difference is durability. Sermorelin is native GHRH(1-29) with a short plasma half-life on the order of 10-12 minutes [3]. CJC-1295 is engineered to last: a D-Ala2 substitution resists the enzyme that chews up the native peptide, and a Drug Affinity Complex (DAC) — a group that latches onto serum albumin — extends its presence in circulation for days. The short native half-life is exactly what motivated those longer-acting analogs in the first place [3]; the broader analog-development arc, from native GHRH to stabilized agonists, is the subject of the recent review literature [14]. The practical contrast: sermorelin is the brief, physiologic pulse-maker; CJC-1295 with DAC is the sustained-exposure variant. For a head-to-head with the stabilized analog used most often as drug-class evidence in this corpus, see [sermorelin vs tesamorelin](/vs-tesamorelin). --- A corkboard reading of the sermorelin literature, riso-clipped and red-strung — every GHRH(1-29) finding pinned to the study that measured it, the body-composition data taped where it belongs as tesamorelin, the frontier wound-healing and oncology signals stamped provisional, and the torn-open clipping where the adult-safety evidence runs out left in plain view; 'get' here means get the literature, and nothing on this board is dosed, dispensed, or sold.